Aurobindo Pharma Limited announced the completion of a United States Food and Drug Administration (US FDA) inspection at Unit-I of its wholly owned subsidiary, Eugia Pharma Specialities Ltd., located in Telangana.

The US FDA conducted the inspection at the formulation manufacturing facility from February 16 to February 27, 2026. At the conclusion of the inspection, the regulatory agency issued four observations in the Form 483.

The company stated that it will submit its response to the US FDA within the prescribed timelines in accordance with regulatory procedures. The observations were issued as part of the routine inspection process followed by the US regulator for facilities supplying pharmaceutical products to the United States market.

Eugia Unit-I operates as a formulation manufacturing facility supporting regulated market supplies, including exports to the US. The inspection outcome forms part of ongoing regulatory compliance and quality oversight applicable to pharmaceutical manufacturing sites serving global markets.

Aurobindo Pharma clarified that the inspection outcome does not have any impact on the company’s financials, operations, or existing business activities. The facility continues to operate in line with established manufacturing and compliance processes while the company proceeds with its regulatory response to the observations.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!